What Haemate P 500 Treats: Main Uses and Benefits

Haemate P 500 is a targeted therapeutic concentrate that is commonly used to manage bleeding and bleeding risk associated with inherited deficiencies of crucial clotting proteins. Its primary role involves supporting hemostasis (the body's process for stopping blood loss). This medicine is applied in clinical settings for patients with Hemophilia A and all types of Von Willebrand Disease (VWD).

It is applied in conditions marked by a lack of necessary clotting factors and helps manage the resulting systemic imbalance. The product is relevant for managing acute, sudden bleeding episodes, such as internal bleeds into joints (hemarthrosis) and muscles (hematoma), and is commonly used for routine prophylaxis to reduce the frequency of recurrent or episodic manifestations over time. This medicine is also relevant in high-risk clinical contexts, including perioperative management during and after surgery. This contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

---

Quick Fact: Therapeutic Focus: Acute Bleeding

Category	Therapeutic Focus
Main Indications	Hemophilia A, all types of VWD
Core Symptom Managed	Bleeding episodes that interfere with daily functioning
Benefit	Helps ease the overall symptom burden

Regulatory References

1. DailyMed listing for HUMATE-P

This section outlines the official population eligibility and non-eligibility rules for Haemate P500 (Humate-P) as documented in regulatory labeling.

---

Eligibility Scope

Eligibility Category	Official Regulatory Statement
Populations for whom use is allowed	Adults with Hemophilia A; Adult and pediatric patients with Von Willebrand Disease (VWD).
Populations for whom use is contraindicated	Individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.
Age-related eligibility rules	Adults are eligible for both Hemophilia A and VWD; pediatric patients are eligible for VWD.
Pregnancy and lactation eligibility status	No human or animal data are available. Use is permitted only if clearly needed during pregnancy and lactation.
Eligibility-related restrictions	Use in mild to moderate VWD is conditional on desmopressin (DDAVP) being inadequate.
	Monitoring is required for patients with A, B, and AB blood groups due to risk of hemolysis with large or frequent doses.

---

Eligibility Classifications (High-Level)

Classification Type	Statement / Context
Eligibility severity classification	Contraindicated (Absolute exclusion due to severe systemic hypersensitivity).
Eligibility-context constraints	Conditional Use (Use only if desmopressin is inadequate); Required Monitoring (Patients with specific blood types or thrombosis risk factors).

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in individuals with a history of severe allergic response to factor VIII or von Willebrand factor preparations.
• Use is allowed for adults with Hemophilia A and adult and pediatric patients with VWD.
• Use during pregnancy and lactation is permitted only if clearly needed, due to insufficient safety data.

Connection to the overall eligibility profile (2–4 sentences): The regulatory profile strictly defines who can and cannot use Haemate P500 by establishing an absolute contraindication based on prior severe allergic response to factor products. Beyond this exclusion, the profile explicitly allows use for specified age and disease populations, while imposing conditional use rules—such as requiring monitoring for patients with certain blood groups and restricting use in mild VWD until desmopressin inadequacy is established. The lack of reproductive safety data mandates use only if clearly needed.

Interactions with other medicines and products

The official regulatory documentation for Haemate P500 (Coagulation Factor VIII/von Willebrand Factor Complex, Human) defines the interaction profile based on two main categories: pharmaceutical incompatibility and specific pharmacodynamic effects.

---

Administration-Timing and Procedural Restrictions

The reconstituted solution is subject to a mandatory pharmaceutical incompatibility rule. The medicine must not be mixed with any other medicinal products, diluents, or solvents in the same infusion line or syringe. This restriction is explicitly stated in prescribing information to prevent potential chemical changes to the factor complex, such as precipitation or loss of activity.

---

Documented Drug-Drug Interaction Cautions

Regulatory documents note the potential for highly clinically significant pharmacodynamic interactions when co-administered with other specialized antihemophilic agents. Specifically, the combination with substances such as Concizumab-mtci and Fitusiran is highlighted in official sources due to their concurrent and complex effects on the blood clotting system, which may result in an additive effect on coagulation.

---

Food and Metabolic Interactions

The official prescribing information contains no documented interaction profile with food or drinks. Additionally, the regulatory documentation does not state any formal pharmacokinetic interactions related to the cytochrome P450 enzyme system or specific drug transporters. The interaction profile is thus simplified outside of the defined coagulation and administration domains.

Replenishing Essential Coagulation Factors

This medicine acts through a direct replacement mechanism, supplying highly purified forms of Factor VIII (FVIII) and von Willebrand Factor (VWF). The introduction of these molecules elevates the concentration of FVIII and VWF within the plasma, engaging the coagulation pathway.

---

Restoring the Coagulation Cascade

The supplied Factor VIII acts as a critical co-factor in the intrinsic coagulation cascade. Its mechanism involves forming the tenase complex ( FVIIIa/ IXa), which specifically catalyzes the activation of Factor X. This sequence initiates the downstream enzymatic cascade leading to the generation of thrombin and, ultimately, the subsequent formation of a fibrin mesh.

---

Stabilizing Factor Activity and Platelet Adhesion

The von Willebrand Factor component serves a dual mechanistic role. It acts as a carrier protein, binding to FVIII, protecting it from inactivation by endogenous proteases, which increases the half-life of FVIII in circulation. VWF also mediates platelet adhesion to the site of vascular injury. The combined action influences both platelet adhesion and the enzymatic cascade.

How to Use Haemate P500

Haemate P500 is a plasma-derived concentrate that is administered exclusively via intravenous (IV) infusion. The product is supplied as a lyophilized powder and solvent that must be carefully reconstituted immediately before use. Dosing is highly individualized and calculated using International Units (IU) per kilogram of the patient's body weight, based on the specific target levels required for either von Willebrand Factor (VWF:RCo) or Factor VIII (FVIII:C).

---

Official Administration and Preparation

The preparation process requires aseptic technique. Before reconstitution, both the powder and solvent vials must be brought to room temperature (up to 25°C). The powder is mixed with the solvent by gently swirling; shaking is prohibited. The reconstituted solution must be administered within three hours and must not be refrigerated during that time. The infusion rate should not exceed 4 milliliters per minute. This medicine must not be mixed with any other solutions or diluents.

---

Standard Dosage Patterns

Indication	Initial Dose (IU/kg)	Frequency Pattern	Duration Concept
VWD Bleeding Episodes	40 to 80 IU VWF:RCo/kg	Repeat every 8 to 12 hours	Short-term until bleed resolution
Hemophilia A Prophylaxis	20 to 40 IU FVIII/kg	Intermittent use, typically every 2 to 3 days	Part of a long-term plan
Surgical Procedures	Initial dose 1-2 hours pre-op	Repeat every 12 to 24 hours post-op	Continued until wound healing is achieved (e.g., ≥ 7 days)

The standard dosage for acute VWD bleeding is between 40 and 80 IU VWF:RCo/kg. For patients undergoing major surgery, the therapy is maintained every 12 to 24 hours post-operatively for at least seven days, or until healing is complete. The product is indicated for use in pediatric patients, with dosing generally following the same weight-based principles as adults.

Recent Clinical Evidence

Haemate P500 is a plasma-derived concentrate containing Factor VIII (FVIII) and von Willebrand Factor (VWF). Clinical research has primarily focused on its use in patients with von Willebrand disease (VWD) and Hemophilia A.

---

Studies in von Willebrand Disease (VWD)

Studies have investigated the concentrate's use for bleeding episodes and surgical prophylaxis in VWD patients, particularly those with Type 3 VWD or severe Type 2 disease who have not responded adequately to desmopressin.

• VWF:RCo Levels: Trials assessed the activity of VWF Ristocetin Cofactor (VWF:RCo) following administration, finding that target levels needed for hemostasis were generally reached.
• Bleeding Episodes: Research evaluated the effectiveness of the concentrate in controlling acute bleeding events across different anatomical sites, reporting successful hemostasis in the majority of episodes treated.

---

Studies in Hemophilia A

While primarily known for its VWD indication, the FVIII content of Haemate P500 has been investigated for use in patients with Hemophilia A (FVIII deficiency).

• FVIII Levels: Studies included pharmacokinetic assessments to measure the increase in plasma FVIII levels after infusion, finding a predictable correlation between the administered dose and the measured plasma concentration.
• Treatment Protocols: Protocols for studies focused on on-demand treatment of bleeding episodes, including joint bleeds and muscle hemorrhages, and evaluated outcomes based on the clinical resolution of the episode.

---

Safety and Tolerability

Safety studies have focused on the tolerability of the concentrate. The most frequently reported adverse events in clinical trials were generally mild and included headache, rash, and allergic reactions. As a plasma-derived product, clinical data tracks the risk of transmitting infectious agents, noting modern manufacturing processes include multiple validated steps for viral inactivation and removal.

Key Studies & References

1. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery
2. Haemate P/Humate-P: a systematic review [Historical Overview and Clinical Efficacy]
3. HUMATE-P (antihemophilic factor/von willebrand factor complex- human kit) - DailyMed [U.S. Package Insert]

Common questions about Haemate P500 (FAQ)

Q: Does Haemate P500 treat all types of von Willebrand disease?

Official product information states that this medicine applies to all types of von Willebrand Disease (VWD). For patients with mild or moderate VWD, its use is specified for situations where the synthetic medicine desmopressin (DDAVP) is known or suspected to be inadequate.

Q: Are there any long-term health concerns associated with using Haemate P500?

Official documents note the potential for thromboembolic events (blood clots), particularly when the medicine is used frequently or at high doses in patients with von Willebrand Disease. For this reason, official labels describe the need for monitoring by a healthcare provider for any events related to abnormal blood clotting.

Q: What are the signs of a hypersensitivity reaction to Haemate P500?

Early signs of a severe allergic reaction (hypersensitivity) are listed in official documents. These signs can include hives, rash, itching, swelling of the face or throat, chest tightness, and trouble breathing.

Q: What happens if Haemate P500 is given too quickly?

The medicine is officially instructed to be infused slowly at a maximum rate of 4 milliliters per minute. Official safety guidelines specify that the infusion must be halted or slowed down if a patient experiences signs of a reaction, such as a rapid heart rate.

Q: How long does it usually take to administer Haemate P500?

The official instructions require the infusion rate not to exceed 4 milliliters per minute. Because the total volume administered is based on the patient’s calculated dose, the total time for the infusion will vary for each individual.

Q: How long does Haemate P500 stay in the body?

The official clinical pharmacology data describes the median half-life of the von Willebrand Factor (VWF) component to be approximately 15.6 hours. This half-life measurement provides a scientific estimate of how long the medicine's activity lasts, but the exact duration can differ from person to person.

Q: Is Haemate P500 use generally restricted for people over the age of 65?

The product label specifies approved use in adult patients with Hemophilia A, which includes the elderly population. Official product information does not note a specific age-related dose adjustment or restriction for people over the age of 65.

Q: What should a person do if they notice swelling or pain at the injection site?

Regulatory reports indicate that localized reactions such as infusion site pain, redness (erythema), and rash have been reported after administration. Official safety instructions specify that any unexpected or persistent reaction should be reported to a healthcare provider.

Q: Is Haemate P500 used for purposes other than Hemophilia A and VWD?

Official regulatory documents define the approved uses as the treatment and prevention of bleeding in adults with Hemophilia A and in adults and children with von Willebrand Disease (VWD). No other uses are listed in the official indications.

Q: What kind of monitoring is typically required when a patient uses Haemate P500?

Official product labels describe the need for frequent monitoring of the patient's Factor VIII (FVIII) levels to allow for dose adjustment. Monitoring is also described as necessary for any events related to abnormal blood clotting.

Q: Can Haemate P500 be administered outside of a hospital setting?

The official prescribing information defines detailed preparation and administration procedures. These procedures indicate that administration is to be conducted under the direction of a physician or a specialist bleeding disorders clinic.

Q: What is the difference between Haemate P500 and DDAVP (desmopressin)?

Haemate P500 is a plasma-derived factor concentrate containing active human Factor VIII and von Willebrand Factor. In contrast, DDAVP (desmopressin) is a synthetic medicine. Haemate P500 is specifically indicated for use when DDAVP is known or suspected to be inadequate for managing mild VWD.

Q: Why is Haemate P500 administered through the vein?

The medicine is explicitly labeled for intravenous use only. This delivery method is necessary for the coagulation factors to be delivered directly into the bloodstream to replace the missing or deficient factors needed for clotting.

Q: What information is provided about the purification process of Haemate P500?

Official documents state the product is purified from the cold insoluble fraction of human plasma. The manufacturing steps involve techniques like cryoprecipitation, adsorption/precipitation steps, and pasteurization to ensure purity and viral safety.

Q: Is it normal to feel a metallic taste after getting Haemate P500?

An altered or abnormal sense of taste, known scientifically as dysgeusia, is listed in regulatory sources as one of the documented adverse reactions related to the Nervous System.

How to Store and Dispose of Haemate P 500

The storage of Haemate P 500 (Factor VIII/vWF Complex) must comply with specific temperature, container, and stability rules defined in regulatory labeling.

Storage Requirements

Condition	Requirement
Unreconstituted Product	Store between 2°C and 8°C (refrigerated). Must be stored in the original outer carton to protect from light.
Alternative Storage	May be stored once at room temperature (up to 25°C/77°F) for a single period of up to 6 months.
Prohibited Conditions	Do not freeze the product. Do not return the reconstituted solution to the refrigerator.
Stability After Mixing	The solution must be used within 3 hours after reconstitution.
Child Safety	Keep the medicine out of the sight and reach of children.

---

Disposal

Disposal of unused or expired product and waste material must be done in accordance with local requirements. The product should not be disposed of via wastewater or household trash.